Activity

specifically improved dual-task cost, which reflects the ability of synchronizing concurrent tasks.

Coronavirus disease 2019 (COVID-19) is a global public health problem that has already caused more than 662,000 deaths worldwide. Although the clinical manifestations of COVID-19 are dominated by respiratory symptoms, some patients present other severe damage such as cardiovascular, renal and liver injury or/and multiple organ failure, suggesting a spread of the SARS-CoV-2 in blood. Recent ultrasensitive polymerase chain reaction (PCR) technology now allows absolute quantification of nucleic acids in plasma. We herein intended to use the droplet-based digital PCR technology to obtain sensitive detection and precise quantification of plasma SARS-CoV-2 viral load (SARS-CoV-2 RNAaemia) in hospitalized COVID-19 patients.

Fifty-eight consecutive COVID-19 patients with pneumonia 8 to 12 days after onset of symptoms and 12 healthy controls were analyzed. Disease severity was categorized as mild-to-moderate in 17 patients, severe in 16 patients and critical in 26 patients. Plasma SARS-CoV-2 RNAaemia was quantified by droplet digital Crystal Digital PCR™ next-generation technology (Stilla Technologies, Villejuif, France).

Overall, SARS-CoV-2 RNAaemia was detected in 43 (74.1%) patients. Prevalence of positive SARS-CoV-2 RNAaemia correlated with disease severity, ranging from 53% in mild-to-moderate patients to 88% in critically ill patients (p=0.036). Levels of SARS-CoV-2 RNAaemia were associated with severity (p=0.035). Among nine patients who experienced clinical deterioration during follow-up, eight had positive SARS-CoV-2 RNAaemia at baseline while only one critical patient with undetectable SARS-CoV-2 RNAaemia at the time of analysis died at day 27.

SARS-CoV-2 RNAaemia measured by droplet-based digital PCR constitutes a promising prognosis biomarker in COVID-19 patients.

SARS-CoV-2 RNAaemia measured by droplet-based digital PCR constitutes a promising prognosis biomarker in COVID-19 patients.Temperature and salinity are important regulators of mangrove range limits and productivity, but the physiological responses of mangroves to the interactive effects of temperature and salinity remain uncertain. We tested the hypothesis that salinity alters photosynthetic responses to seasonal changes in temperature and vapor pressure deficit (D), as well as thermal acclimation _of leaf respiration in black mangrove (Avicennia germinans). To test this hypothesis, we grew seedlings of A. germinans in an outdoor experiment for ~ 12 months under four treatments spanning 0 to 55 ppt porewater salinity. We repeatedly measured seedling growth and in situ rates of leaf net photosynthesis (Asat) and stomatal conductance to water vapor (gs) at prevailing leaf temperatures, along with estimated rates of Rubisco carboxylation (Vcmax) and electron transport for RuBP regeneration (Jmax), and measured rates of leaf respiration at 25 °C (Rarea25). We developed empirical models describing the seasonal response of leaf gas exchange and photosynthetic capacity to leaf temperature and D, and the response of Rarea25 to changes in mean daily air temperature. We tested the effect of salinity on model parameters. Over time, salinity had weak or inconsistent effects on Asat, gs and Rarea25. Salinity also had little effect on the biochemical parameters of photosynthesis (Vcmax, Jmax) and individual measurements of Asat, gs, Vcmax and Jmax showed a similar response to seasonal changes in temperature and D across all salinity treatments. Individual measurements of Rarea25 showed a similar inverse relationship with mean daily air temperature across all salinity treatments. We conclude that photosynthetic responses to seasonal changes in temperature and D, as well as seasonal temperature acclimation of leaf R, are largely consistent across a range of salinities in A. germinans. These results might simplify predictions of photosynthetic and respiratory responses to temperature in young mangroves.

Patients with cancer are particularly vulnerable to Clostridioides difficile infection (CDI). selleckchem Guidelines recommend a two-step diagnostic algorithm to differentiate carriers from CDI; however, there is limited data for this approach while including other confounding risk factors for diarrhea such as radiation, cytotoxic chemotherapy and adoptive cell based therapies.

We conducted a prospective, non-interventional, single center, cohort study of cancer patients with acute diarrhea and C. difficile. Identified in stools by nucleic acid amplification tests (NAAT) and culture. Fecal toxin A/B was detected by enzyme immunoassay (EIA) and isolates were ribotyped using 16s rRNA fluorescent sequencing. Patients were followed for 90 days to compare outcomes according to malignancy type, infecting ribotype, and EIA status.

We followed 227 patients with a positive NAAT. Of these, 87% were hospitalized and 83% had an active malignancy. EIA was confirmed positive in 80/227 (35%) of patients. Those with EIA+ were older (60 ± 18 yrs. vs. 54 ±1 9 yrs., p=0.01), more likely to fail therapy [24/80 (30%) vs. 26/147 (18%), p=0.04] and experience recurrence [20/80 (25%) vs. 21/147(14%), p<0.05]. We found a low prevalence (22%) of ribotypes historically associated with poor outcomes (002, 018, 027, 56, F078-126, 244) but their presence were associated with treatment failure [17/50 (34%) vs. 33/177 (19%), p=0.02].

When compared to cancer patients with fecal NAAT+/EIA, patients with NAAT+/EIA+ CDI are less likely to respond to therapy and more likely to experience recurrence; particularly when due to ribotypes associated with poor outcomes.

When compared to cancer patients with fecal NAAT+/EIA, patients with NAAT+/EIA+ CDI are less likely to respond to therapy and more likely to experience recurrence; particularly when due to ribotypes associated with poor outcomes.Successful solid organ transplantation reflects meticulous attention to the details of immunosuppression, balancing risks for graft rejection against risks for infection. The ‘net state of immune suppression’ is a conceptual framework of all factors contributing to infectious risk. Assays which measure immune function in the immunosuppressed transplant recipient relative to infectious risk and allograft function are lacking. The best measures of integrated immune function may be quantitative viral loads to assess the individual’s ability to control latent viral infections. Few studies address adjustment of immunosuppression during active infections. Thus, confronted with infection in solid organ recipients, the management of immunosuppression is based largely on clinical experience. This review examines known measures of immune function and the immunologic effects of common immunosuppressive drugs and available studies reporting modification of drug regimens for specific infections. These data provide a conceptual framework for the management of immunosuppression during infection in organ recipients.